Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: Current state and problems

Dong Youn Hwang, Dae Sung Kim, Dong Wook Kim

Research output: Contribution to journalReview article

30 Citations (Scopus)


Cell therapy using human embryonic stem cells (hESCs) is a promising therapeutic option for Parkinson's disease (PD), an incurable neurodegenerative disease. A prerequisite for clinical application of hESCs for PD is an efficient and strict differentiation of hESCs into midbrain dopamine (mDA) neuron-like cells, which would be directly translated into high effectiveness of the therapy with minimum risk of undesirable side effects. Due to fruitful efforts from many laboratories, a variety of strategies for improving efficiency of dopaminergic differentiation from hESCs have been developed, mostly by optimizing culture conditions, genetic modification, and modulating intracellular signaling pathways. The rapid advances in the fields of dopaminergic differentiation of hESCs, prevention of tumor formation, and establishment of safe human induced pluripotent stem cells (hiPSCs) would open the door to highly effective, tumor-free, and immune rejection-free cell therapy for PD in the near future.

Original languageEnglish
Pages (from-to)292-301
Number of pages10
JournalJournal of cellular biochemistry
Issue number2
Publication statusPublished - 2010 Feb 1
Externally publishedYes



  • Dopamine neuron differentiation
  • Human ES/IPS cells
  • Pakinson's disease

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this